The vaccine has been developed by Siberia's Vector Institute, which completed early-stage human trials of the vaccine last week. Russia registered its first vaccine candidate, developed by Moscow's Gamaleya Institute, in August. Late-stage trials, involving at least 40,000 people, are ongoing.
No comments:
Post a Comment